NewBiologix

NewBiologix, founded in 2023 and headquartered in Lausanne, Switzerland, is positioning itself as a significant contender in the Biotechnology, Health Care, and Life Sciences sectors. The company's mission, encapsulated in their slogan, "Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders," underscores their commitment to transformative healthcare solutions.

Their core innovation, a proprietary DNA integration platform, aims to revolutionize the engineering of human and mammalian cell lines, enhancing the production of viral vectors crucial for gene therapies. This breakthrough has the potential to significantly impact the biopharma industry's approach to disease treatment.

In May 2023, NewBiologix secured a substantial Fr.45.00M Series A investment, backed by notable investors such as Nicolas Mermod, Igor Fish, and the Recipharm Venture Fund. This financial backing supports their ambitious R&D trajectory and expansion plans.